Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists

Journal of Clinical Oncology

Volumn 23, Issue 11, 2005, Pages 2477-2492

  Dowsett, Mitch ^a   Ebbs, Steve R ^a   Dixon, J Michael ^a   Skene, Anthony ^a   Griffith, Clive ^a   Boeddinghaus, Irene ^a   Salter, Janine ^a   Detre, Simone ^a   Hills, Margaret ^a   Ashley, Susan ^a   Francis, Stephen ^a   Walsh, Geraldine ^a   Smith, Ian E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KI 67 ANTIGEN; NITRILE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR BIOPSY; ADJUVANT THERAPY; AGED; BREAST TUMOR; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTMENOPAUSE; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 20244374413     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.559     Document Type: Article

References (21)

1. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003
2. Harper-Wynne CL, Sacks NP, Shenton K, et al: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026-1035, 2002
3. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531, 2003
4. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
5. Smith IE, Dowsett M: Neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women: The IMmediate Preoperative Arimidex, tamoxifen or Combined with Tamoxifen (IMPACT) trial. J Clin Oncol 23: in press
6. Dowsett M, Smith IE, Ebbs SR, et al: Short term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s-958s, 2005(2 pt 2)
7. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
8. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
9. Johnston SR, Boeddinghaus IM, Riddler S, et al: Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59:3646-3651, 1999
10. Kyprianou N, English HF, Davidson NE, et al: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166, 1991
11. World Health Organization: WHO handbook for reporting results of cancer treatment, volume 48. Geneva, Switzerland, WHO Offset Publications, 1979
12. Clarke RB, Laidlaw IJ, Jones LJ, et al: Effect of tamoxifen on Ki67 labelling index of human breast tumors and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67:606-611, 1993
13. Ellis PA, Smith IE, Detre S, et al: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48:107-116, 1998
14. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
15. Dowsett M, Haynes BP: Hormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255-263, 2003
16. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
17. Jensen EV, DesSombre ER: Steroid hormone binding and hormone receptors, in Holland JF, Frei E III, Bast RC Jr, et al (eds): Cancer Medicine. 4th Edition. Baltimore, MD, Williams and Wilkins, 1996, pp 1049-1060
18. Cui X, Zhang P, Deng W, et al: Insulin-like growth factor-l inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588, 2003
19. Dowsett M, on behalf of the ATAC Trialists' Group: Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82:S7, 2003 (abstr 5; suppl 1)
20. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458, 2001
21. Howell A, Harland RN, Barnes DM, et al: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47:300-304, 1987